Marker Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
MRKR Nasdaq 2830 markertherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Marker Therapeutics, Inc.

US High Growth Tech Stocks to Watch - Dec 15th, 2025 10:39 am
3 High Growth Tech Stocks To Watch In The US Market - Dec 15th, 2025 4:38 am
High Growth Tech Stocks In The US Market With Potential - Dec 11th, 2025 4:38 am
High Growth Tech Stocks to Watch in US December 2025 - Dec 9th, 2025 4:38 am
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates - Nov 14th, 2025 5:00 am
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors - Nov 5th, 2025 5:30 am
Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting - Nov 3rd, 2025 7:15 am
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program - Oct 6th, 2025 5:30 am
Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference - Aug 28th, 2025 6:00 am
Marker Therapeutics (MRKR) Falls 20.6% After Positive Clinical Study - Aug 27th, 2025 10:02 am
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma - Aug 26th, 2025 5:00 am
Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference - Jul 30th, 2025 6:00 am
Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation - Jul 11th, 2025 5:01 am
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma - Jun 17th, 2025 6:00 am
Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma - May 20th, 2025 6:00 am
Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies - May 19th, 2025 6:00 am
Marker Therapeutics Full Year 2024 Earnings: Misses Expectations - Apr 2nd, 2025 4:31 am
Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference - Apr 1st, 2025 6:00 am
Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results - Mar 31st, 2025 6:45 am
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Feb 25th, 2025 5:00 am